Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes.
OBJECTIVE
The growth factors transforming growth factor-B (TGF-B) and epidermal growth factor (EGF) have both been implicated in the hypertrophic structural changes in the vasculature that are characteristic features of both human and experimental diabetes. Recently, tranilast (N(3,4-dimethoxycinnamoyl)anthranilic acid), a drug used in the treatment of allergic and dermatological diseases, has also been reported to inhibit transforming growth factor-B (TGF-B)-mediated collagen formation. However, its effects on vascular hypertrophy in diabetes are unknown. The present study thus sought to determine the effects of tranilast on both TGF-B and EGF expression and mast cells in mediating the trophic vascular changes in experimental diabetes.


METHODS
Vessel morphology, growth factors and collagen gene expression and matrix deposition were examined in the mesenteric arteries of control rats treated with or without tranilast, and streptozotocin-induced diabetic Sprague-Dawley rats treated with or without tranilast (200 mg/kg/day) during a 3-week period.


RESULTS
Compared with control animals, diabetic rats had significantly increased vessel weight, wall: lumen ratio, ECM accumulation, gene expression of TGF-B1, EGF, and both alpha1 (I) and alpha1 (IV) collagen. Tranilast treatment did not influence plasma glucose or systemic blood pressure. However, tranilast significantly reduced mesenteric weight, wall: lumen ratio and matrix deposition and also attenuated the overexpression of TGF-B1, EGF, and both alpha1 (I) and alpha1 (IV) collagen mRNA in diabetic rats.


CONCLUSIONS
These findings indicate that tranilast ameliorates pathological vascular changes observed in experimental diabetes in association with reduced growth factor expression independent of blood glucose or systemic blood pressure.
Bonnet
F
F
Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg West, Victoria. fab.so.bonnet@free.fr
Cao
Z
Z
Cooper
M E
ME
Cox
A J
AJ
Kelly
D J
DJ
Gilbert
R E
RE
D000818:Animals; D001483:Base Sequence; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D003094:Collagen / Q000235:genetics; D017931:DNA Primers; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D004815:Epidermal Growth Factor / Q000235:genetics; D005786:Gene Expression Regulation / Q000187:drug effects; D006133:Growth Substances / Q000235:genetics / Q000378:metabolism*; D006984:Hypertrophy; D007150:Immunohistochemistry; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016212:Transforming Growth Factor beta / Q000235:genetics; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
D017931:DNA Primers; D006133:Growth Substances; D010975:Platelet Aggregation Inhibitors; D016212:Transforming Growth Factor beta; D062367:ortho-Aminobenzoates; D004815:Epidermal Growth Factor; D003094:Collagen; C012293:tranilast